Penumbra, Inc. Reports Second Quarter 2025 Financial Results
Penumbra (NYSE:PEN), a leading thrombectomy company, reported strong Q2 2025 financial results with revenue of $339.5 million, up 13.4% year-over-year. The company demonstrated robust performance in key segments, with U.S. Thrombectomy revenue reaching $188.5 million, a 22.6% increase, and U.S. VTE revenue growing 42% compared to Q2 2024.
The company achieved net income of $45.3 million with a 13.3% margin and adjusted EBITDA of $61.4 million with an 18.1% margin. Gross profit improved to $224.0 million with a 66.0% margin. Based on strong performance, Penumbra increased its 2025 revenue guidance to $1.355-1.370 billion, representing 13-15% growth over 2024.
Penumbra (NYSE:PEN), un'azienda leader nel settore della trombectomia, ha riportato risultati finanziari solidi per il secondo trimestre del 2025 con ricavi di 339,5 milioni di dollari, in aumento del 13,4% rispetto all'anno precedente. L'azienda ha mostrato una performance robusta nei segmenti chiave, con ricavi da trombectomia negli Stati Uniti pari a 188,5 milioni di dollari, un incremento del 22,6%, e ricavi da VTE negli USA cresciuti del 42% rispetto al secondo trimestre del 2024.
L'azienda ha raggiunto un utile netto di 45,3 milioni di dollari con un margine del 13,3% e un EBITDA rettificato di 61,4 milioni di dollari con un margine del 18,1%. Il profitto lordo è migliorato a 224,0 milioni di dollari con un margine del 66,0%. Grazie a queste solide performance, Penumbra ha rivisto al rialzo le previsioni dei ricavi per il 2025 a 1,355-1,370 miliardi di dollari, rappresentando una crescita del 13-15% rispetto al 2024.
Penumbra (NYSE:PEN), una empresa líder en trombectomía, reportó sólidos resultados financieros en el segundo trimestre de 2025 con ingresos de 339,5 millones de dólares, un aumento del 13,4% interanual. La compañía mostró un desempeño fuerte en segmentos clave, con ingresos por trombectomía en EE.UU. alcanzando los 188,5 millones de dólares, un incremento del 22,6%, y los ingresos por TVP en EE.UU. creciendo un 42% en comparación con el segundo trimestre de 2024.
La empresa logró un ingreso neto de 45,3 millones de dólares con un margen del 13,3% y un EBITDA ajustado de 61,4 millones de dólares con un margen del 18,1%. La ganancia bruta mejoró a 224,0 millones de dólares con un margen del 66,0%. Basándose en este sólido desempeño, Penumbra aumentó su guía de ingresos para 2025 a 1,355-1,370 mil millones de dólares, lo que representa un crecimiento del 13-15% respecto a 2024.
Penumbra (NYSE:PEN)는 선도적인 혈전제거술 회사로서 2025년 2분기 강력한 재무 실적을 보고했습니다. 매출액은 3억 3,950만 달러로 전년 동기 대비 13.4% 증가했습니다. 회사는 주요 부문에서 견고한 성과를 보였으며, 미국 혈전제거술 매출은 1억 8,850만 달러로 22.6% 증가했고, 미국 VTE 매출은 2024년 2분기 대비 42% 성장했습니다.
순이익은 4,530만 달러로 13.3%의 마진을 기록했으며, 조정 EBITDA는 6,140만 달러로 18.1% 마진을 보였습니다. 총이익은 2억 2,400만 달러로 66.0% 마진으로 개선되었습니다. 강력한 실적을 바탕으로 Penumbra는 2025년 매출 전망을 13억 5,500만~13억 7,000만 달러로 상향 조정했으며, 이는 2024년 대비 13-15% 성장에 해당합니다.
Penumbra (NYSE:PEN), une entreprise leader dans le domaine de la thrombectomie, a publié de solides résultats financiers pour le deuxième trimestre 2025 avec un chiffre d'affaires de 339,5 millions de dollars, en hausse de 13,4 % par rapport à l'année précédente. La société a démontré une performance robuste dans les segments clés, avec un chiffre d'affaires thrombectomie aux États-Unis atteignant 188,5 millions de dollars, soit une augmentation de 22,6 %, et un chiffre d'affaires VTE aux États-Unis en croissance de 42 % par rapport au deuxième trimestre 2024.
La société a réalisé un résultat net de 45,3 millions de dollars avec une marge de 13,3 % et un EBITDA ajusté de 61,4 millions de dollars avec une marge de 18,1 %. Le bénéfice brut s'est amélioré à 224,0 millions de dollars avec une marge de 66,0 %. Grâce à cette solide performance, Penumbra a relevé ses prévisions de chiffre d'affaires pour 2025 à 1,355-1,370 milliard de dollars, représentant une croissance de 13 à 15 % par rapport à 2024.
Penumbra (NYSE:PEN), ein führendes Unternehmen im Bereich Thrombektomie, meldete starke Finanzergebnisse für das zweite Quartal 2025 mit Umsätzen von 339,5 Millionen US-Dollar, was einem Anstieg von 13,4 % im Jahresvergleich entspricht. Das Unternehmen zeigte eine robuste Leistung in wichtigen Segmenten, wobei der Umsatz mit Thrombektomie in den USA 188,5 Millionen US-Dollar erreichte, ein Plus von 22,6 %, und der Umsatz mit VTE in den USA im Vergleich zum zweiten Quartal 2024 um 42 % wuchs.
Das Unternehmen erzielte einen Nettoertrag von 45,3 Millionen US-Dollar mit einer Marge von 13,3 % und ein bereinigtes EBITDA von 61,4 Millionen US-Dollar mit einer Marge von 18,1 %. Der Bruttogewinn verbesserte sich auf 224,0 Millionen US-Dollar mit einer Marge von 66,0 %. Aufgrund der starken Leistung hat Penumbra seine Umsatzprognose für 2025 auf 1,355-1,370 Milliarden US-Dollar angehoben, was einem Wachstum von 13-15 % gegenüber 2024 entspricht.
- Revenue increased 13.4% to $339.5 million in Q2 2025
- U.S. Thrombectomy revenue grew 22.6% year-over-year
- U.S. VTE revenue increased 42% compared to prior year
- Gross margin improved to 66.0% from 54.4% year-over-year
- Company raised full-year 2025 revenue guidance to $1.355-1.370 billion
- International revenue decreased 3.2% (5.8% in constant currency)
- Operating expenses increased to $183.2 million from $164.5 million year-over-year
Insights
Penumbra delivered strong Q2 results with 13.4% revenue growth and impressive 42% VTE growth, while raising full-year guidance.
Penumbra's Q2 results demonstrate robust momentum in its core thrombectomy business. Total revenue reached
Profitability metrics showed substantial improvement. Operating margin reached
The company's guidance increase is particularly noteworthy. Management now projects full-year revenue of
Particularly encouraging is management's expectation for sequential gross margin expansion in the second half of 2025, driven by favorable product mix and productivity improvements. This suggests the company is successfully transitioning toward higher-margin products while optimizing its manufacturing processes.
The
- Revenue of
$339.5 million 13.4% or12.7% in constant currency1, compared to the second quarter of 2024. - U.S. Thrombectomy revenue of
$188 22.6% compared to the second quarter of 2024.U.S. VTE revenue increased42% compared to the same period a year ago. - Income from operations of
$40.8 million 12.0% in the second quarter of 2025. - Net income of
$45.3 million $61 13.3% and adjusted EBITDA margin1 of18.1% in the second quarter of 2025.
Second Quarter 2025 Financial Results
Total revenue increased to
Gross profit for the second quarter of 2025 was
Total operating expenses and non-GAAP operating expenses1 were
Income from operations and non-GAAP income from operations1 was
1 | See "Non-GAAP Financial Measures" for important information about our use of non-GAAP measures. |
Updated Full Year 2025 Financial Outlook
The Company is increasing its guidance for 2025 total revenue to a range of
Webcast and Conference Call Information
Penumbra, Inc. will host a conference call to discuss the second quarter 2025 financial results after market close on Tuesday, July 29, 2025 at 4:30 PM Eastern Time. The conference call can be accessed live over the phone by dialing (888) 596-4144 (conference id: 6572573), or the webcast can be accessed on the "Events and Presentations" section under the "Investors" tab of the Company's website at: www.penumbrainc.com. The webcast will be available on the Company's website for at least two weeks following the completion of the call.
About Penumbra
Penumbra, Inc., the world's leading thrombectomy company, is focused on developing the most innovative technologies for challenging medical conditions such as ischemic stroke, venous thromboembolism such as pulmonary embolism, and acute limb ischemia. Our broad portfolio, which includes computer assisted vacuum thrombectomy (CAVT), centers on removing blood clots from head-to-toe with speed, safety and simplicity. By pioneering these innovations, we support healthcare providers, hospitals and clinics in more than 100 countries, working to improve patient outcomes and quality of life. For more information, visit www.penumbrainc.com and connect on Instagram, LinkedIn, and X.
Non-GAAP Financial Measures
In addition to financial measures prepared in accordance with
Constant Currency. The Company's constant currency revenue disclosures estimate the impact of changes in foreign currency rates on the translation of the Company's current period revenue as compared to the applicable comparable period in the prior year. This impact is derived by taking the current local currency revenue and translating it into
Non-GAAP operating expenses, non-GAAP income (loss) from operations, non-GAAP net income (loss), and non-GAAP diluted EPS. The adjustments to the GAAP financial measures reflect the exclusion of:
- the effect of the amortization of finite lived intangible assets acquired in connection with the Sixense acquisition over their estimated useful lives;
- the excess tax benefits associated with share-based compensation arrangements;
- non-recurring litigation related expenses; and
- non-cash long-lived asset impairment charges related to the impairment of our immersive healthcare asset group.
Adjusted EBITDA and adjusted EBITDA margin. The Company's adjusted EBITDA reflects the exclusion from GAAP net income (loss) of:
- non-cash operating charges such as stock-based compensation, depreciation and amortization, and impairment charges;
- non-operating items such as interest income, interest expense, and provision for (benefit from) income taxes; and
- non-recurring litigation related expenses.
Full reconciliation of these non-GAAP measures to the most comparable GAAP measures is set forth in the tables below.
Our management believes the non-GAAP financial measures disclosed in this press release are useful to investors in assessing the operating performance of our business and provide meaningful comparisons to prior periods and thus a more complete understanding of our business than could be obtained absent this disclosure. Specifically, we consider the change in constant currency revenue as a useful metric as it provides an alternative framework for assessing how our underlying business performed excluding the effect of foreign currency rate fluctuations. We consider non-GAAP operating expenses, non-GAAP income (loss) from operations, non-GAAP net income (loss), and non-GAAP diluted EPS useful metrics as they provide an alternative framework for assessing how our underlying business performed excluding non-cash long-lived asset impairment charges related to the impairment of our immersive healthcare asset group, the amortization expense of finite lived intangible assets acquired in connection with the Sixense acquisition, the excess tax benefits associated with share-based compensation arrangements, and expenses related to certain litigation matters that we have determined are not a normal or recurring part of our business, including settlement costs and legal fees. Further, we consider adjusted EBITDA and adjusted EBITDA margin useful metrics as they provide an alternative framework for assessing how our underlying business performed excluding non-cash operating charges such as stock-based compensation, depreciation and amortization, and impairment charges, non-operating items such as interest income, interest expense, and provision for (benefit from) income taxes and non-recurring litigation related expenses.
The non-GAAP financial measures included in this press release may be different from, and therefore may not be comparable to, similarly titled measures used by other companies. These non-GAAP measures should not be considered in isolation or as alternatives to GAAP measures. We urge investors to review the reconciliation of these non-GAAP financial measures to the comparable GAAP financial measures included in this press release, and not to rely on any single financial measure to evaluate our business.
Forward-Looking Statements
Except for historical information, certain statements in this press release are forward-looking in nature and are subject to risks, uncertainties and assumptions about us. Our business and operations are subject to a variety of risks and uncertainties and, consequently, actual results may differ materially from those projected by any forward-looking statements. Factors that could cause actual results to differ from those projected include, but are not limited to: failure to sustain or grow profitability or generate positive cash flows; failure to effectively introduce and market new products; delays in product introductions; significant competition; inability to further penetrate our current customer base, expand our user base and increase the frequency of use of our products by our customers; inability to achieve or maintain satisfactory pricing and margins; manufacturing difficulties; permanent write-downs or write-offs of our inventory or other assets; product defects or failures; unfavorable outcomes in clinical trials; inability to maintain our culture as we grow; fluctuations in foreign currency exchange rates; potential adverse regulatory actions; and the potential impact of any acquisitions, mergers, dispositions, joint ventures or investments we may make. These risks and uncertainties, as well as others, are discussed in greater detail in our filings with the Securities and Exchange Commission ("SEC"), including our Annual Report on Form 10-K for the year ended December 31, 2024 filed with the SEC on February 18, 2025. There may be additional risks of which we are not presently aware or that we currently believe are immaterial which could have an adverse impact on our business. Any forward-looking statements are based on our current expectations, estimates and assumptions regarding future events and are applicable only as of the dates of such statements. We make no commitment to revise or update any forward-looking statements in order to reflect events or circumstances that may change.
Penumbra, Inc. Condensed Consolidated Balance Sheets (unaudited) (in thousands) | ||||
June 30, 2025 | December 31, 2024 | |||
Assets | ||||
Current assets: | ||||
Cash and cash equivalents | $ 421,768 | $ 324,404 | ||
Marketable investments | 2,795 | 15,727 | ||
Accounts receivable, net | 175,536 | 167,668 | ||
Inventories | 427,628 | 406,737 | ||
Prepaid expenses and other current assets | 37,757 | 36,589 | ||
Total current assets | 1,065,484 | 951,125 | ||
Property and equipment, net | 84,825 | 62,641 | ||
Operating lease right-of-use assets | 174,059 | 177,787 | ||
Finance lease right-of-use assets | 27,606 | 28,018 | ||
Intangible assets, net | 6,552 | 6,513 | ||
Goodwill | 166,752 | 165,826 | ||
Deferred taxes | 109,141 | 100,332 | ||
Other non-current assets | 40,390 | 40,939 | ||
Total assets | $ 1,674,809 | $ 1,533,181 | ||
Liabilities and Stockholders' Equity | ||||
Current liabilities: | ||||
Accounts payable | $ 28,121 | $ 31,326 | ||
Accrued liabilities | 114,389 | 112,429 | ||
Current operating lease liabilities | 12,855 | 12,221 | ||
Current finance lease liabilities | 2,396 | 2,369 | ||
Total current liabilities | 157,761 | 158,345 | ||
Non-current operating lease liabilities | 183,493 | 187,068 | ||
Non-current finance lease liabilities | 21,785 | 21,731 | ||
Other non-current liabilities | 17,819 | 15,106 | ||
Total liabilities | 380,858 | 382,250 | ||
Stockholders' equity: | ||||
Common stock | 39 | 38 | ||
Additional paid-in capital | 1,146,260 | 1,096,732 | ||
Accumulated other comprehensive income (loss) | 3,155 | (5,843) | ||
Retained earnings | 144,497 | 60,004 | ||
Total stockholders' equity | 1,293,951 | 1,150,931 | ||
Total liabilities and stockholders' equity | $ 1,674,809 | $ 1,533,181 | ||
Penumbra, Inc. Condensed Consolidated Statements of Operations (unaudited) (in thousands, except share and per share amounts) | ||||||||
Three Months Ended June 30, | Six Months Ended June 30, | |||||||
2025 | 2024 | 2025 | 2024 | |||||
Revenue | $ 339,455 | $ 299,403 | $ 663,595 | $ 578,058 | ||||
Cost of revenue | 115,445 | 136,574 | 223,702 | 234,090 | ||||
Gross profit | 224,010 | 162,829 | 439,893 | 343,968 | ||||
Operating expenses: | ||||||||
Research and development | 23,218 | 24,942 | 45,295 | 49,568 | ||||
Sales, general and administrative | 159,964 | 141,903 | 313,420 | 286,315 | ||||
Impairment charge | — | 76,945 | — | 76,945 | ||||
Total operating expenses | 183,182 | 243,790 | 358,715 | 412,828 | ||||
Income (loss) from operations | 40,828 | (80,961) | 81,178 | (68,860) | ||||
Interest and other income, net | 4,482 | 3,087 | 7,990 | 5,612 | ||||
Income (loss) before income taxes | 45,310 | (77,874) | 89,168 | (63,248) | ||||
Provision for (benefit from) income taxes | 40 | (17,674) | 4,675 | (14,050) | ||||
Net income (loss) | $ 45,270 | $ (60,200) | $ 84,493 | $ (49,198) | ||||
Net income (loss) per share: | ||||||||
Basic | $ 1.17 | $ (1.55) | $ 2.18 | $ (1.27) | ||||
Diluted | $ 1.15 | $ (1.55) | $ 2.15 | $ (1.27) | ||||
Weighted average shares outstanding: | ||||||||
Basic | 38,834,917 | 38,793,341 | 38,699,307 | 38,755,337 | ||||
Diluted | 39,245,953 | 38,793,341 | 39,214,027 | 38,755,337 | ||||
Penumbra, Inc. Reconciliation of GAAP Operating Expenses and GAAP Income (Loss) from Operations to Non-GAAP Operating Expenses and (unaudited) (in thousands) | ||||||||
Three Months Ended June 30, | Six Months Ended June 30, | |||||||
2025 | 2024 | 2025 | 2024 | |||||
GAAP operating expenses | $ 183,182 | $ 243,790 | $ 358,715 | $ 412,828 | ||||
GAAP operating expenses includes the effect of the following | ||||||||
Impairment charge2 | — | 76,945 | — | 76,945 | ||||
Non-recurring litigation related expenses | — | — | — | 4,823 | ||||
Amortization of finite lived intangible assets acquired | — | 2,380 | — | 4,759 | ||||
Non-GAAP operating expenses | $ 183,182 | $ 164,465 | $ 358,715 | $ 326,301 | ||||
GAAP income (loss) from operations | $ 40,828 | $ (80,961) | $ 81,178 | $ (68,860) | ||||
GAAP income (loss) from operations includes the effect of the | ||||||||
Impairment charge2 | — | 76,945 | — | 76,945 | ||||
Non-recurring litigation related expenses | — | — | — | 4,823 | ||||
Amortization of finite lived intangible assets acquired | — | 2,380 | — | 4,759 | ||||
Non-GAAP income (loss) from operations | $ 40,828 | $ (1,636) | $ 81,178 | $ 17,667 | ||||
__________________ | |
1 | See "Non-GAAP Financial Measures" for important information about our use of non-GAAP measures. |
2 | Represents charges associated with the impairment of the immersive healthcare asset group during the three months ended June 30, 2024. |
Penumbra, Inc. Reconciliation of GAAP Net Income (Loss) and GAAP Diluted EPS to Non-GAAP Net Income (Loss) and Non-GAAP Diluted EPS1 (unaudited) (in thousands, except share and per share amounts) | ||||||||||||||||
Three Months Ended June 30, 2025 | Three Months Ended June 30, 2024 | Six Months Ended | Six Months Ended | |||||||||||||
Net | Diluted | Net loss | Diluted | Net | Diluted | Net (loss) | Diluted | |||||||||
GAAP net income (loss) | $ 45,270 | $ 1.15 | $ (60,200) | $ (1.55) | $ 84,493 | $ 2.15 | $ (49,198) | $ (1.27) | ||||||||
GAAP net income (loss) includes the effect of the | ||||||||||||||||
Impairment charge2 | — | — | 76,945 | 1.98 | — | — | 76,945 | 1.97 | ||||||||
Non-recurring litigation related expenses | — | — | — | — | — | — | 4,823 | 0.12 | ||||||||
Amortization of finite lived intangible assets | — | — | 2,380 | 0.06 | — | — | 4,759 | 0.12 | ||||||||
Tax effects on the non-GAAP adjustments above3 | — | — | (19,117) | (0.49) | — | — | (20,853) | (0.52) | ||||||||
Excess tax benefits related to stock compensation | (11,541) | (0.29) | (119) | 0.00 | (18,134) | (0.46) | (406) | (0.01) | ||||||||
Non-GAAP net income (loss) | $ 33,729 | $ 0.86 | $ (111) | $ — | $ 66,359 | $ 1.69 | $ 16,070 | $ 0.41 | ||||||||
GAAP diluted EPS | $ 1.15 | $ (1.55) | $ 2.15 | $ (1.27) | ||||||||||||
Non-GAAP diluted EPS | $ 0.86 | $ 0.00 | $ 1.69 | $ 0.41 | ||||||||||||
Weighted average shares outstanding used to compute: | ||||||||||||||||
GAAP diluted EPS | 39,245,953 | 38,793,341 | 39,214,027 | 38,755,337 | ||||||||||||
Non-GAAP diluted EPS4 | 39,245,953 | 38,793,341 | 39,214,027 | 39,398,553 | ||||||||||||
__________________ | |
1 | See "Non-GAAP Financial Measures" for important information about our use of non-GAAP measures. |
2 | Represents charges associated with the impairment of the immersive healthcare asset group during the three months ended June 30, 2024. |
3 | For the three and six months ended June 30, 2024, management used a combined federal and state tax rate of |
4 | For the purposes of calculating non-GAAP diluted EPS for the six months ended June 30, 2024, non-GAAP diluted weighted average shares |
Penumbra, Inc. Reconciliation of GAAP Net Income (Loss) and GAAP Net Income (Loss) Margin to Adjusted EBITDA and Adjusted EBITDA (unaudited) (in thousands, except for percentages) | ||||||||
Three Months Ended June 30, | Six Months Ended June 30, | |||||||
2025 | 2024 | 2025 | 2024 | |||||
GAAP net income (loss) | $ 45,270 | $ (60,200) | $ 84,493 | $ (49,198) | ||||
Adjustments to GAAP net income (loss): | ||||||||
Depreciation and amortization expense | 5,507 | 7,647 | 10,522 | 15,166 | ||||
Interest income, net | (3,670) | (3,313) | (6,734) | (6,204) | ||||
Provision for (benefit from) income taxes | 40 | (17,674) | 4,675 | (14,050) | ||||
Stock-based compensation expense | 14,234 | 9,560 | 28,019 | 23,129 | ||||
Impairment charge2 | — | 76,945 | — | 76,945 | ||||
Non-recurring litigation related expenses | — | — | — | 4,823 | ||||
Adjusted EBITDA | $ 61,381 | $ 12,965 | $ 120,975 | $ 50,611 | ||||
Revenue | $ 339,455 | $ 299,403 | $ 663,595 | $ 578,058 | ||||
Adjusted EBITDA | $ 61,381 | $ 12,965 | $ 120,975 | $ 50,611 | ||||
GAAP net income (loss) margin | 13.3 % | (20.1) % | 12.7 % | (8.5) % | ||||
Adjusted EBITDA margin | 18.1 % | 4.3 % | 18.2 % | 8.8 % | ||||
__________________ | |
1 | See "Non-GAAP Financial Measures" for important information about our use of non-GAAP measures. |
2 | Represents charges associated with the impairment of the immersive healthcare asset group during the three months ended June 30, 2024. |
Penumbra, Inc. Reconciliation of Revenue Growth by Geographic Regions to Constant Currency Revenue Growth1 (unaudited) (in thousands, except for percentages) | ||||||||||||||
Three Months Ended June 30, | Reported Change | FX Impact | Constant Currency Change | |||||||||||
2025 | 2024 | $ | % | $ | $ | % | ||||||||
$ 260,818 | $ 218,180 | $ 42,638 | 19.5 % | $ — | $ 42,638 | 19.5 % | ||||||||
International | 78,637 | 81,223 | (2,586) | (3.2) % | (2,141) | (4,727) | (5.8) % | |||||||
Total | $ 339,455 | $ 299,403 | $ 40,052 | 13.4 % | $ (2,141) | $ 37,911 | 12.7 % | |||||||
Six Months Ended June 30, | Reported Change | FX Impact | Constant Currency Change | |||||||||||
2025 | 2024 | $ | % | $ | $ | % | ||||||||
$ 517,678 | $ 427,824 | $ 89,854 | 21.0 % | $ — | $ 89,854 | 21.0 % | ||||||||
International | 145,917 | 150,234 | (4,317) | (2.9) % | (483) | (4,800) | (3.2) % | |||||||
Total | $ 663,595 | $ 578,058 | $ 85,537 | 14.8 % | $ (483) | $ 85,054 | 14.7 % | |||||||
Penumbra, Inc. Reconciliation of Revenue Change by Product Categories to Constant Currency Revenue Growth1 (unaudited) (in thousands, except for percentages) | ||||||||||||||
Three Months Ended June 30, | Reported Change | FX Impact | Constant Currency Change | |||||||||||
2025 | 2024 | $ | % | $ | $ | % | ||||||||
Thrombectomy | $ 230,256 | $ 203,502 | $ 26,754 | 13.1 % | $ (1,147) | $ 25,607 | 12.6 % | |||||||
Embolization and Access | 109,199 | 95,901 | 13,298 | 13.9 % | (994) | 12,304 | 12.8 % | |||||||
Total | $ 339,455 | $ 299,403 | $ 40,052 | 13.4 % | $ (2,141) | $ 37,911 | 12.7 % | |||||||
Six Months Ended June 30, | Reported Change | FX Impact | Constant Currency Change | |||||||||||
2025 | 2024 | $ | % | $ | $ | % | ||||||||
Thrombectomy | $ 456,800 | $ 391,205 | $ 65,595 | 16.8 % | $ (224) | $ 65,371 | 16.7 % | |||||||
Embolization and Access | 206,795 | 186,853 | 19,942 | 10.7 % | (259) | 19,683 | 10.5 % | |||||||
Total | $ 663,595 | $ 578,058 | $ 85,537 | 14.8 % | $ (483) | $ 85,054 | 14.7 % | |||||||
Penumbra, Inc. Reconciliation of Revenue Change by Product Categories and Geographic Regions to Constant Currency Revenue Growth1 (unaudited) (in thousands, except for percentages) | ||||||||||||||
Three Months Ended June 30, | Reported Change | FX Impact | Constant Currency Change | |||||||||||
2025 | 2024 | $ | % | $ | $ | % | ||||||||
Thrombectomy | ||||||||||||||
$ 188,533 | $ 153,728 | $ 34,805 | 22.6 % | $ — | $ 34,805 | 22.6 % | ||||||||
International | 41,723 | 49,774 | (8,051) | (16.2) % | (1,147) | (9,198) | (18.5) % | |||||||
Total Thrombectomy | 230,256 | 203,502 | 26,754 | 13.1 % | (1,147) | 25,607 | 12.6 % | |||||||
Embolization and Access | ||||||||||||||
72,285 | 64,452 | 7,833 | 12.2 % | — | 7,833 | 12.2 % | ||||||||
International | 36,914 | 31,449 | 5,465 | 17.4 % | (994) | 4,471 | 14.2 % | |||||||
Total Embolization and Access | 109,199 | 95,901 | 13,298 | 13.9 % | (994) | 12,304 | 12.8 % | |||||||
Total | $ 339,455 | $ 299,403 | $ 40,052 | 13.4 % | $ (2,141) | $ 37,911 | 12.7 % | |||||||
Six Months Ended June 30, | Reported Change | FX Impact | Constant Currency Change | |||||||||||
2025 | 2024 | $ | % | $ | $ | % | ||||||||
Thrombectomy | ||||||||||||||
$ 376,425 | $ 304,013 | $ 72,412 | 23.8 % | $ — | $ 72,412 | 23.8 % | ||||||||
International | 80,375 | 87,192 | (6,817) | (7.8) % | (224) | (7,041) | (8.1) % | |||||||
Total Thrombectomy | 456,800 | 391,205 | 65,595 | 16.8 % | (224) | 65,371 | 16.7 % | |||||||
Embolization and Access | ||||||||||||||
141,253 | 123,811 | 17,442 | 14.1 % | — | 17,442 | 14.1 % | ||||||||
International | 65,542 | 63,042 | 2,500 | 4.0 % | (259) | 2,241 | 3.6 % | |||||||
Total Embolization and Access | 206,795 | 186,853 | 19,942 | 10.7 % | (259) | 19,683 | 10.5 % | |||||||
Total | $ 663,595 | $ 578,058 | $ 85,537 | 14.8 % | $ (483) | $ 85,054 | 14.7 % | |||||||
__________________ | |
1 | See "Non-GAAP Financial Measures" for important information about our use of non-GAAP measures. |
Investor Relations
Penumbra, Inc.
investors@penumbrainc.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/penumbra-inc-reports-second-quarter-2025-financial-results-302516497.html
SOURCE Penumbra, Inc.
FAQ
What was Penumbra's (PEN) revenue for Q2 2025?
How much did Penumbra's U.S. Thrombectomy revenue grow in Q2 2025?
What is Penumbra's (PEN) revenue guidance for full year 2025?
What was Penumbra's gross margin in Q2 2025?
How did Penumbra's international business perform in Q2 2025?
